Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Biocryst Pharmaceuticals 

2190 Parkway Lake Drive

Birmingham  Alabama  35244  U.S.A.
Phone: 205-444-4600 Fax:




Affinimark Technologies Inc. 

 Company News
Biocryst Pharmaceuticals (BCRX) Initiates Opus-2: A Clinical Trial Of BCX4161 In Patients With Hereditary Angioedema 12/18/2014 7:41:07 AM
Biocryst Pharmaceuticals (BCRX) Announces Initiation Of A Phase 1 Clinical Trial Of BCX4430 For The Treatment Of Hemorrhagic Fever Viruses 12/15/2014 7:21:55 AM
Biocryst Pharmaceuticals (BCRX) To Present At Two Upcoming Investor Conferences 11/20/2014 2:08:44 PM
Biocryst Pharmaceuticals (BCRX) Reports Third Quarter 2014 Financial Results 11/6/2014 10:52:05 AM
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/20/2014 3:28:01 AM
Biocryst Pharmaceuticals (BCRX) To Launch NHP Ebola Drug Safety, Efficacy Studies "Within Weeks" 10/10/2014 3:22:11 PM
Biocryst Pharmaceuticals (BCRX) Release: RAPIVAB™ Trial Results For The Treatment Of Influenza To Be Presented At IDWeek 2014 10/8/2014 7:13:57 AM
Biocryst Pharmaceuticals (BCRX) Announces Late Breaker Presentation Of Opus-1 Phase 2 Trial Results At The 23rd EADV Congress 10/7/2014 7:34:13 AM
Biocryst Pharmaceuticals (BCRX) Receives Additional National Institute of Allergy And Infectious Diseases (NIAID) Funding For Manufacture And Development Of BCX4430 To Treat Hemorrhagic Virus Diseases 9/18/2014 11:20:04 AM
Biocryst Pharmaceuticals (BCRX) Announces RAPIVAB™ Trial Results For The Treatment Of Influenza At The ICAAC 2014 Meeting 9/8/2014 7:38:22 AM